{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:56:41Z","timestamp":1782266201391,"version":"3.54.5"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.det.2020.12.012","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T10:16:02Z","timestamp":1612952162000},"page":"195-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Nail Psoriasis in Older Adults"],"prefix":"10.1016","volume":"39","author":[{"given":"Jose W.","family":"Ricardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1087-0024.2003.09102.x","article-title":"Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction","volume":"9","author":"Stern","year":"2004","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.det.2020.12.012_bib3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.det.2020.12.012_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0001-7310(09)73372-1","article-title":"Progress in understanding the immunopathogenesis of psoriasis","volume":"100","author":"Mak","year":"2009","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.det.2020.12.012_bib5","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.2147\/DDDT.S136986","article-title":"New insight into the pathogenesis of nail psoriasis and overview of treatment strategies","volume":"11","author":"Ventura","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1084\/jem.20091669","article-title":"Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines","volume":"207","author":"Kisand","year":"2010","journal-title":"J\u00a0Exp Med"},{"issue":"12","key":"10.1016\/j.det.2020.12.012_bib7","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1111\/ijd.12562","article-title":"Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis","volume":"53","author":"Taheri Sarvtin","year":"2014","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2020.12.012_bib8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaad.2018.03.062","article-title":"Onychomycosis: clinical overview and diagnosis","volume":"80","author":"Lipner","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2 Pt 1","key":"10.1016\/j.det.2020.12.012_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1067\/mjd.2000.104794","article-title":"Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients","volume":"43","author":"Gupta","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2020.12.012_bib10","article-title":"Nail psoriasis in older adults: epidemiology, diagnosis and topical therapy","author":"Ricardo","year":"2020","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.det.2020.12.012_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2019.01.072","article-title":"Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus","volume":"81","author":"Rigopoulos","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib12","first-page":"78","article-title":"Treatment of nail psoriasis with a modified regimen of steroid injections","volume":"18","author":"Saleem","year":"2008","journal-title":"J\u00a0Coll Physicians Surg Pak"},{"issue":"4","key":"10.1016\/j.det.2020.12.012_bib13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ced.13087","article-title":"Role of nail bed methotrexate injections in isolated nail psoriasis: conventional drug via an unconventional route","volume":"42","author":"Grover","year":"2017","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.det.2020.12.012_bib14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11597000-000000000-00000","article-title":"Nail psoriasis: a review","volume":"13","author":"Tan","year":"2012","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.det.2020.12.012_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4103\/ijdvl.IJDVL_73_16","article-title":"Intramatricial injections for nail psoriasis: an open-label comparative study of triamcinolone, methotrexate, and cyclosporine","volume":"84","author":"Mittal","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"10.1016\/j.det.2020.12.012_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1365-2133.1998.02031.x","article-title":"A\u00a0simplified protocol of steroid injection for psoriatic nail dystrophy","volume":"138","author":"de Berker","year":"1998","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/09546634.2018.1476647","article-title":"A\u00a0randomized comparison of efficacy and safety of intralesional triamcinolone injection and clobetasol propionate ointment for psoriatic nails","volume":"30","author":"Boontaveeyuwat","year":"2019","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.det.2020.12.012_bib18","article-title":"Air cooling for improved analgesia during local anesthetic infiltration for nail surgery","author":"Ricardo","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib19","first-page":"76","article-title":"Pain-minimizing strategies for nail surgery","volume":"101","author":"Lipner","year":"2018","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.det.2020.12.012_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0304-3959(95)00102-6","article-title":"The effect of age on A delta- and C-fibre thermal pain perception","volume":"64","author":"Chakour","year":"1996","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.det.2020.12.012_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.sder.2008.12.003","article-title":"Management of psoriatic nail disease","volume":"28","author":"de Berker","year":"2009","journal-title":"Semin Cutan Med Surg"},{"issue":"6","key":"10.1016\/j.det.2020.12.012_bib22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-016-0564-5","article-title":"Nail psoriasis: a review of treatment options","volume":"76","author":"Pasch","year":"2016","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.det.2020.12.012_bib23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/14712598.2018.1504016","article-title":"An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly","volume":"18","author":"Di Lernia","year":"2018","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"10.1016\/j.det.2020.12.012_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1468-3083.2010.03927.x","article-title":"Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study","volume":"25","author":"Gumusel","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.det.2020.12.012_bib25","first-page":"1039","article-title":"Effectiveness of systemic treatment agents on psoriatic nails: a comparative study","volume":"12","author":"Demirsoy","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.det.2020.12.012_bib26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5114\/pdia.2013.35619","article-title":"Topical calcineurin inhibitors in dermatology. Part I: properties, method and effectiveness of drug use","volume":"30","author":"Gutfreund","year":"2013","journal-title":"Postepy Dermatol Alergol"},{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/120347540400800208","article-title":"Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol","volume":"8","author":"Feliciani","year":"2004","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"11","key":"10.1016\/j.det.2020.12.012_bib28","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3899\/jrheum.110242","article-title":"Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial","volume":"38","author":"Karanikolas","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.det.2020.12.012_bib29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2340\/00015555-1719","article-title":"Efficacy and safety of systemic treatments for psoriasis in elderly patients","volume":"94","author":"Piaserico","year":"2014","journal-title":"Acta Derm Venereol"},{"issue":"Suppl 2","key":"10.1016\/j.det.2020.12.012_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-3083.2011.03992.x","article-title":"Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis","volume":"25","author":"Maza","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2020.12.012_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/archdermatol.2008.600","article-title":"Evaluation of the efficacy of acitretin therapy for nail psoriasis","volume":"145","author":"Tosti","year":"2009","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib32","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1590\/S0365-05962012000200010","article-title":"NAPSI utilization as an evaluation method of nail psoriasis in patients using acitretin","volume":"87","author":"Mukai","year":"2012","journal-title":"An Bras Dermatol"},{"issue":"4","key":"10.1016\/j.det.2020.12.012_bib33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","article-title":"Apremilast: a review in psoriasis and psoriatic arthritis","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.det.2020.12.012_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2020.12.012_bib35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2020.12.012_bib36","first-page":"495","article-title":"Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis","volume":"40","author":"Zerilli","year":"2015","journal-title":"P\u00a0T"},{"issue":"1","key":"10.1016\/j.det.2020.12.012_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/jamadermatol.2014.2983","article-title":"Treatment of nail psoriasis: best practice recommendations from the medical board of the National Psoriasis Foundation","volume":"151","author":"Crowley","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2020.12.012_bib38","doi-asserted-by":"crossref","first-page":"508178","DOI":"10.1155\/2014\/508178","article-title":"Serum levels of TNF-alpha, IL-12\/23 p40, and IL-17 in psoriatic patients with and without nail psoriasis: a cross-sectional study","volume":"2014","author":"Kyriakou","year":"2014","journal-title":"Scientific World Journal"},{"issue":"5","key":"10.1016\/j.det.2020.12.012_bib39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1468-3083.2010.03826.x","article-title":"Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients","volume":"25","author":"Fabroni","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2020.12.012_bib40","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/09546634.2011.646939","article-title":"Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study","volume":"24","author":"Kyriakou","year":"2013","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.det.2020.12.012_bib41","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40257-018-0388-z","article-title":"Effect of age of onset of psoriasis on clinical outcomes with systemic treatment in the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"19","author":"Singh","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"10.1016\/j.det.2020.12.012_bib42","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1468-3083.2009.03211.x","article-title":"Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis","volume":"23","author":"Luger","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.det.2020.12.012_bib43","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5114\/pdia.2015.53320","article-title":"Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis","volume":"32","author":"Pirowska","year":"2015","journal-title":"Postepy Dermatol Alergol"},{"issue":"3","key":"10.1016\/j.det.2020.12.012_bib44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1468-3083.2011.04349.x","article-title":"Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus","volume":"26","author":"Langley","year":"2012","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.det.2020.12.012_bib45","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/14712598.2013.783561","article-title":"Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing etanercept, infliximab and adalimumab","volume":"13","author":"Al-Mutairi","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.det.2020.12.012_bib46","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjd.17351","article-title":"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"issue":"13","key":"10.1016\/j.det.2020.12.012_bib47","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti\u2013interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.det.2020.12.012_bib48","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/jdv.12996","article-title":"Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis","volume":"29","author":"Langley","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","article-title":"Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies","volume":"35","author":"Korber","year":"2018","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib50","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjd.12632","article-title":"Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1","volume":"170","author":"Rich","year":"2014","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.det.2020.12.012_bib51","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/1346-8138.12653","article-title":"Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis","volume":"41","author":"Hayashi","year":"2014","journal-title":"J\u00a0Dermatol"},{"issue":"1","key":"10.1016\/j.det.2020.12.012_bib52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ijpharm.2016.05.022","article-title":"Nail disorders in older people, and aspects of their pharmaceutical treatment","volume":"512","author":"Murdan","year":"2016","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.det.2020.12.012_bib54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/09546634.2011.631979","article-title":"How psoriasis patients perceive, obtain, and use biologic agents: survey from an academic medical center","volume":"24","author":"Kamangar","year":"2013","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.det.2020.12.012_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2133.1974.tb06724.x","article-title":"Intralesional triamcinolone acetonide using the Port-O-Jet and needle injections in localized dermatoses","volume":"91","author":"Bleeker","year":"1974","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2020.12.012_bib56","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2310\/7750.2013.13078","article-title":"Treatment of nail psoriasis with intralesional triamcinolone acetonide using a needle-free jet injector: a prospective trial","volume":"18","author":"Nantel-Battista","year":"2014","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"17","key":"10.1016\/j.det.2020.12.012_bib57","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","article-title":"A\u00a052-week trial comparing briakinumab with methotrexate in patients with psoriasis","volume":"365","author":"Reich","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.det.2020.12.012_bib58","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1468-3083.2010.03938.x","article-title":"Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy)","volume":"25","author":"Sanchez-Regana","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.det.2020.12.012_bib59","first-page":"1065","article-title":"A\u00a036-week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis","volume":"11","author":"Bardazzi","year":"2013","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"5","key":"10.1016\/j.det.2020.12.012_bib60","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1468-3083.2009.03453.x","article-title":"Treatment of nail psoriasis with adalimumab: an open label unblinded study","volume":"24","author":"Rigopoulos","year":"2010","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib61","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ard.2009.111856","article-title":"Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions","volume":"69","author":"Van den Bosch","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.det.2020.12.012_bib62","first-page":"958","article-title":"Ixekizumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: results from UNCOVER 3","volume":"15","author":"Dennehy","year":"2016","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"12","key":"10.1016\/j.det.2020.12.012_bib63","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jdv.12359","article-title":"Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial","volume":"28","author":"Paul","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2020.12.012_bib64","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","article-title":"Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial","volume":"39","author":"Igarashi","year":"2012","journal-title":"J\u00a0Dermatol"},{"issue":"2","key":"10.1016\/j.det.2020.12.012_bib65","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/09546634.2011.607796","article-title":"Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study","volume":"24","author":"Patsatsi","year":"2013","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"11","key":"10.1016\/j.det.2020.12.012_bib66","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/1346-8138.13956","article-title":"Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: subgroup analyses from a randomized, placebo-controlled phase 3 trial","volume":"44","author":"Abe","year":"2017","journal-title":"J\u00a0Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863520301157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863520301157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:45:10Z","timestamp":1760006710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863520301157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0733863520301157"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2020.12.012","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nail Psoriasis in Older Adults","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2020.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}